NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
Y-mAbs Therapeutics announces new business units for Radiopharmaceuticals and DANYELZA, reporting preliminary revenues of $88 million for 2024. Y-mAbs Therapeutics, Inc. has announced strategic ...
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
Y-mAbs Therapeutics (NASDAQ:YMAB) stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete ...
Y-mAbs is a commercial-stage biotech, and its one commercialized product, Danyelza, brought in $22.8 million for the second quarter and was responsible for all the company's net revenue. Those sales ...
During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of ...
(RTTNews) - Y-mAbs Therapeutics (YMAB) and Nobelpharma have entered into a license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of ...
Monoclonal antibodies (mAbs) are nature's biological warheads, able to target and help eliminate foreign or abnormal agents from the body. In theory, replicating this powerful defense system could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results